Showing 2241-2250 of 3239 results for "".
- HEROES Educational Campaign Highlights Role of Salons in Promoting Skin and Scalp Healthhttps://practicaldermatology.com/news/heroes-educational-campaign-highlights-role-of-salons-in-promoting-skin-and-scalp-health/2461766/The Globa
- Biosimilar Update: Dr. Reddy’s Completes Phase I Study of Proposed Tocilizumab Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-dr-reddys-completes-phase-i-study-of-proposed-tocilizumab-biosimilar/2461765/Dr. Reddy’s Laboratories’ tocilizumab biosimilar candidate, DRL_TC, met its primary and secondary endpoints in a Phase I study. The company is now initiating a global Phase III study with the aim of comparing the efficacy, safety, tolerability and immunogeni
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- Survey Highlights Room for Improvement in AK Awarenesshttps://practicaldermatology.com/news/survey-highlights-room-for-improvement-in-ak-awareness/2461746/As many as 85% of people are unaware of actinic keratosis (AK), according to a new survey from Almirall. The survey of more than 2,500 participants over the age or 35 aimed to understand the level of knowledge about AK and skin health habits within the general population of Spain, Germa
- Almirall, CRG Partner to Develop Novel Preclinical Models for NMSChttps://practicaldermatology.com/news/almirall-crg-partner-to-develop-novel-preclinical-models-for-nmsc/2461741/Almirall and the Centre for Genomic Regulation (CRG) are joining forces to develop and characterize novel preclinical models that will help identify new treatments for non-melanoma skin cancer (NMSC). This partnership, led by Almirall's investigators Dr
- Biosimilar Update: FDA Nod for High-Concentration, Citrate-Free Formulation of Humira Biosimilarhttps://practicaldermatology.com/news/biosimilar-update-fda-nod-for-high-concentration-citrate-free-formulation-of-humira-biosimilar/2461740/The U.S. Food and Drug Administration (FDA) has approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juven
- Wayne State University Dermatology Resident Wins Svider Memorial Scholarship Awardhttps://practicaldermatology.com/news/wayne-state-university-dermatology-resident-wins-svider-memorial-scholarship-award/2461737/Kayla St. Claire, M.D., M.B.A., a Wayne State University School of Medicine dermatology resident, has won the Peter Svider Memorial Resident Scholarship Award. The award is presented annually to a graduating resident or fellow in any graduate medical education program in recognition of
- AAD Survey: Too Few Folks Use Sun Protection During Outdoor Activitieshttps://practicaldermatology.com/news/aad-survey-too-few-folks-use-sun-protection-during-outdoor-activities/2461735/Although 90% of Americans report protecting themselves from the sun when going to beaches or pools, far fewer plan for it before other outdoor activities, according to a recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults. "The head, neck, arms, and l
- Call for Papers: JMIR Dermatology Special Theme Issue on Teledermatologyhttps://practicaldermatology.com/news/call-for-papers-jmir-dermatology-special-theme-issue-on-teledermatology/2461734/JMIR Dermatology—the official journal of the International Society of Teledermatology (ISTD)—and the journal’s guest editors welcome submissions to
- Orlucent Receives FDA Breakthrough Device Designation for Handheld Mole Imaging Systemhttps://practicaldermatology.com/news/orlucent-receives-fda-breakthrough-device-designation-for-handheld-mole-imaging-system/2461733/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for Orlucent’s Skin Fluorescence Imaging System. The Orlucent system is a handheld point-of-care molecular-based imaging system designed to noninvasively identify and clinically assess the pres